Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: PELI1

Gene summary for PELI1

Gene summary.

Gene information	Species	Human
	Gene symbol	PELI1
	Gene ID	57162
	Gene name	pellino E3 ubiquitin protein ligase 1
	Gene Alias	PELI1
	Cytomap	2p14
	Gene Type	protein-coding
	GO ID	GO:0000209
	UniProtAcc	Q53T26

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
57162	PELI1	CCI_1	Human	Cervix	CC	3.13e-09	1.44e+00	0.528
57162	PELI1	CCI_3	Human	Cervix	CC	1.90e-04	6.26e-01	0.516
57162	PELI1	HTA11_3410_2000001011	Human	Colorectum	AD	3.23e-04	-2.96e-01	0.0155
57162	PELI1	HTA11_3361_2000001011	Human	Colorectum	AD	9.65e-06	-5.58e-01	-0.1207
57162	PELI1	HTA11_866_3004761011	Human	Colorectum	AD	3.92e-04	-3.60e-01	0.096
57162	PELI1	HTA11_7696_3000711011	Human	Colorectum	AD	2.19e-02	-3.68e-01	0.0674
57162	PELI1	HTA11_99999971662_82457	Human	Colorectum	MSS	1.12e-03	-3.53e-01	0.3859
57162	PELI1	HTA11_99999973899_84307	Human	Colorectum	MSS	3.61e-03	-5.20e-01	0.2585
57162	PELI1	HTA11_99999974143_84620	Human	Colorectum	MSS	6.66e-04	-3.31e-01	0.3005
57162	PELI1	A015-C-203	Human	Colorectum	FAP	1.22e-19	-3.19e-01	-0.1294
57162	PELI1	A015-C-204	Human	Colorectum	FAP	1.19e-03	-2.66e-01	-0.0228
57162	PELI1	A014-C-040	Human	Colorectum	FAP	4.99e-04	-4.51e-01	-0.1184
57162	PELI1	A002-C-201	Human	Colorectum	FAP	7.12e-13	-3.70e-01	0.0324
57162	PELI1	A001-C-119	Human	Colorectum	FAP	4.08e-08	-3.86e-01	-0.1557
57162	PELI1	A001-C-108	Human	Colorectum	FAP	1.87e-13	-3.70e-01	-0.0272
57162	PELI1	A002-C-205	Human	Colorectum	FAP	8.06e-25	-5.67e-01	-0.1236
57162	PELI1	A015-C-005	Human	Colorectum	FAP	4.36e-02	-1.49e-01	-0.0336
57162	PELI1	A015-C-006	Human	Colorectum	FAP	1.17e-16	-5.66e-01	-0.0994
57162	PELI1	A015-C-106	Human	Colorectum	FAP	1.79e-05	-2.86e-01	-0.0511
57162	PELI1	A002-C-114	Human	Colorectum	FAP	6.59e-18	-5.04e-01	-0.1561

Page: 1 2 3 4 5 6 7 8 9

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:001049810	Cervix	CC	proteasomal protein catabolic process	111/2311	490/18723	8.98e-11	1.58e-08	111
GO:002240710	Cervix	CC	regulation of cell-cell adhesion	103/2311	448/18723	1.78e-10	2.87e-08	103
GO:190332010	Cervix	CC	regulation of protein modification by small protein conjugation or removal	66/2311	242/18723	2.31e-10	3.46e-08	66
GO:003139610	Cervix	CC	regulation of protein ubiquitination	59/2311	210/18723	5.90e-10	7.51e-08	59
GO:00421108	Cervix	CC	T cell activation	107/2311	487/18723	1.24e-09	1.46e-07	107
GO:00508638	Cervix	CC	regulation of T cell activation	80/2311	329/18723	1.28e-09	1.47e-07	80
GO:00071598	Cervix	CC	leukocyte cell-cell adhesion	85/2311	371/18723	8.27e-09	7.07e-07	85
GO:004316110	Cervix	CC	proteasome-mediated ubiquitin-dependent protein catabolic process	91/2311	412/18723	1.65e-08	1.25e-06	91
GO:00071626	Cervix	CC	negative regulation of cell adhesion	72/2311	303/18723	2.36e-08	1.70e-06	72
GO:00026837	Cervix	CC	negative regulation of immune system process	94/2311	434/18723	2.63e-08	1.87e-06	94
GO:19030378	Cervix	CC	regulation of leukocyte cell-cell adhesion	77/2311	336/18723	4.08e-08	2.54e-06	77
GO:00027644	Cervix	CC	immune response-regulating signaling pathway	97/2311	468/18723	1.49e-07	7.07e-06	97
GO:00002097	Cervix	CC	protein polyubiquitination	58/2311	236/18723	1.57e-07	7.41e-06	58
GO:00018197	Cervix	CC	positive regulation of cytokine production	95/2311	467/18723	4.88e-07	1.85e-05	95
GO:00022379	Cervix	CC	response to molecule of bacterial origin	78/2311	363/18723	5.55e-07	2.06e-05	78
GO:00324969	Cervix	CC	response to lipopolysaccharide	74/2311	343/18723	9.15e-07	3.25e-05	74
GO:00420988	Cervix	CC	T cell proliferation	49/2311	199/18723	1.32e-06	4.49e-05	49
GO:00224084	Cervix	CC	negative regulation of cell-cell adhesion	48/2311	196/18723	1.99e-06	6.18e-05	48
GO:00421297	Cervix	CC	regulation of T cell proliferation	43/2311	171/18723	3.21e-06	8.77e-05	43
GO:00510904	Cervix	CC	regulation of DNA-binding transcription factor activity	87/2311	440/18723	4.85e-06	1.22e-04	87

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

PELI1

SNV

Missense_Mutation

c.1156N>T

p.His386Tyr

p.H386Y

Q96FA3

protein_coding

deleterious(0.02)

probably_damaging(0.998)

TCGA-A2-A0EY-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

PELI1

SNV

Missense_Mutation

rs761769713

c.977G>A

p.Arg326His

p.R326H

Q96FA3

protein_coding

deleterious(0.04)

possibly_damaging(0.506)

TCGA-AO-A0J4-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

PELI1

insertion

Frame_Shift_Ins

novel

c.346_347insCCTACGTGAAACCAGATCGGCTCAGCAGAGAGGA

p.Asp116AlafsTer20

p.D116Afs*20

Q96FA3

protein_coding

TCGA-AR-A0TY-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unspecific

Paclitaxel

PELI1

insertion

Frame_Shift_Ins

novel

c.340_341insC

p.Val114AlafsTer3

p.V114Afs*3

Q96FA3

protein_coding

TCGA-B6-A0IB-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Unknown

PELI1

insertion

Frame_Shift_Ins

novel

c.339_340insCTCATACTTTTCATGCAGCCTGTCCCTTTTGTGCACATCAGTTG

p.Val114LeufsTer16

p.V114Lfs*16

Q96FA3

protein_coding

TCGA-B6-A0IB-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Unknown

PELI1

SNV

Missense_Mutation

c.1181C>T

p.Ala394Val

p.A394V

Q96FA3

protein_coding

tolerated(0.84)

benign(0.284)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

PELI1

SNV

Missense_Mutation

c.1174N>T

p.His392Tyr

p.H392Y

Q96FA3

protein_coding

deleterious(0.01)

possibly_damaging(0.876)

TCGA-DS-A1OC-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

gemcitabine

PELI1

SNV

Missense_Mutation

rs761769713

c.977N>A

p.Arg326His

p.R326H

Q96FA3

protein_coding

deleterious(0.04)

possibly_damaging(0.506)

TCGA-MA-AA42-01

Cervix

cervical & endocervical cancer

Female

>=65

I/II

Unknown

PELI1

SNV

Missense_Mutation

c.895N>A

p.Val299Ile

p.V299I

Q96FA3

protein_coding

tolerated(0.31)

benign(0.007)

TCGA-A6-6654-01

Colorectum

colon adenocarcinoma

Female

>=65

III/IV

Chemotherapy

oxaliplatin

PELI1

SNV

Missense_Mutation

rs768293813

c.859A>G

p.Asn287Asp

p.N287D

Q96FA3

protein_coding

deleterious(0)

possibly_damaging(0.627)

TCGA-AA-3833-01

Colorectum

colon adenocarcinoma

Female

<65

I/II

Unknown

Page: 1 2 3 4 5

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1